Clinical trials: Upper Gastrointestinal Disorder
Hepatic Cirrhosis, Liver Fibrosis
A Study of Experimental Medication BMS-986036 Given to Healthy Participants
This is a study of experimental medication BMS-986036 given to healthy participants.
- Conditions
- Hepatic Cirrhosis, Liver Fibrosis, Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
- Trial name
- NCT03445208
- Testing
- BMS-986036
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Heartburn
Esomeprazole And Symptomatic Response In Patients With Or Without An Elevated Risk For Non-Steroidal Anti-Inflammatory Drug (NSAID)-Associated GI Damage
The purpose of this study is to compare the treatment effect in patients with upper gastro-intestinal complaints with an elevated risk for NSAID-associated GI-damage to those without an elevated risk for NSAID-associated damage…
- Trial name
- Synchronise (NCT00524329)
- Volunteers
- 1,220 people
- Sponsor
- AstraZeneca
Liver Fibrosis, Cirrhosis
Fibroscan® and Its Dedicated Probes Efficiency in Obese Patients
The main objective of the study is to evaluate the diagnostic performance of the XL probe for estimating degree of liver fibrosis/cirrhosis in obese patients > 28 kg/m² with various liver diseases in patients with chronic liver…
- Trial name
- NCT00926224
- Testing
- FibroScan M and XL probes
- Where
- 5 sites in Canada
- Volunteers
- 300 people
- Sponsor
- Echosens
Exocrine Pancreatic Insufficiency
Bioavailability of Pancreatic Enzymes in the Human Upper Intestine (Duodenum and Jejunum)
The overall purpose of this research is to demonstrate (or measure) the intestinal availability of lipase, amylase, and protease (enzymes the body has a shortage of) from PANCRECARB® when administered with a meal.
- Trial name
- NCT00749099
- Testing
- pancrelipase
- Volunteers
- 11 people
- Sponsor
- Digestive Care, Inc.
Peptic Ulcer
Study to Assess the Efficacy and Safety of Somatostatin in the Treatment of Acute Severe Upper Gastrointestinal Bleeding
To assess the efficacy and safety of the early administration of somatostatin in infusion during 72 hours plus 2 boluses, compared to placebo in the control of acute severe UGIB with suspicion of PUB.
- Trial name
- NCT00152399
- Testing
- Somatostatin UCB (drug)
- Where
- 22 sites in Belgium, France and 4 more
- Volunteers
- 370 people
- Sponsor
- UCB Pharma
Cough
Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of AG1321001 in Chronic Cougher
This study is for therapeutic confirmation of AG1321001 to evaluate the safety and efficacy as an anti-tussive agent in cough patients.
- Trial name
- NCT00380315
- Testing
- AG1321001(drug)
- Where
- South Korea
- Volunteers
- 396 people
- Sponsor
- Ahn-Gook Pharmaceuticals Co.,Ltd
Alopecia Areata, Depressive Episode
The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
This study series consists of four related studies and aims to explore and describe many important elements of alopecia areata over three key areas: (1) the current epidemiology of alopecia areata, (2) the prevalence and…
- Conditions
- Alopecia Areata, Depressive Episode, Recurrent Depressive Disorder, Anxiety Disorders
- Trial name
- NCT04239521
- Testing
- Exposure of interest (studies 2 & 3).
- Where
- United Kingdom
- Volunteers
- 51,955 people
- Sponsor
- Momentum Data
Dysentery, Dysentery, Bacillary
Safety Study of S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine in Healthy Volunteers Aged Above 3 Months
The purpose of this study is to evaluate safety of S.flexneriza-S.sonnei Bivalent Conjugate Vaccine in healthy volunteers aged above 3 Months.
- Trial name
- NCT03561181
- Testing
- S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Gastroesophageal Reflux Disease
Prevalence of Gastroesophageal Reflux Disease in Primary Care Patients With Upper Gastrointestinal Symptoms
The purpose of this study is to provide data on the gastroesophageal reflux disease (GERD) prevalence as percentage of patients with upper gastrointestinal (GI) symptoms that are identified with GERD using the Gerd-Q…
- Trial name
- NCT01020890
- Where
- 12 sites in Bulgaria
- Volunteers
- 2,210 people
- Sponsor
- AstraZeneca
Patients With Upper Gastro-intestinal Symptoms
Prevalence of Gastroesophageal Reflux Disease (GERD) in Patients With Upper Gastrointestinal Tract Symptoms in Egypt
The purpose of this study is to calculate the prevalence of gastroesophageal reflux disease (GERD) by mean of GERD-Q questionnaire in patients with upper gastrointestinal tract symptoms in Egypt.
- Trial name
- GERD Q NIS (NCT01635959)
- Where
- 21 sites in Egypt
- Volunteers
- 3,170 people
- Sponsor
- AstraZeneca
Upper GI Bleeding
Evaluation of PillCam With Blood-Sensing Feature: A Feasibility Study
1. Primary Scientific Objective Collect human clinical data to sustain the development of blood detection sensor and optimize its algorithm and parameters Preliminary evaluation of blood detection performances in human. 2.
- Trial name
- NCT01448382
- Testing
- PillCam® capsule with Given PillCam® Platform
- Where
- Israel
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Medtronic - MITG
Chronic Gastrointestinal Graft vs Host Disease
Study of orBec® as Monotherapy in the Treatment of Patients With Upper GI Symptoms Caused by Chronic Graft Versus Host Disease (GVHD)
Use of an oral topically-active glucocorticoid with limited side effects may control the gastrointestinal inflammatory process of GVHD and minimize glucocorticoid exposure.
- Trial name
- NCT01925950
- Testing
- orBec
- Where
- 3 sites in United States
- Volunteers
- 2 people
- Sponsor
- Soligenix
Upper Gastrointestinal Bleeding
Safety & Efficacy of Omeprazole Sodium Bicarbonate for the Prevention of Upper GI Bleeding in the Critically Ill
Critically ill patients are at an increased risk of having upper gastrointestinal (GI) bleeding due to stress related mucosal damage.
- Trial name
- NCT00045799
- Testing
- Omeprazole sodium bicarbonate immediate release PWD/FS, Cimetidine IV
- Where
- 58 sites in United States
- Volunteers
- 354 people
- Sponsor
- Bausch Health Americas, Inc.
Non-Small Cell Lung Carcinoma, Breast Cancer
A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002)
This is a two-part study to test the safety, tolerability, and immune response for V934/V935 vaccine using a new prime-boost regimen in participants with selected solid tumors.
- Conditions
- Non-Small Cell Lung Carcinoma, Breast Cancer, Melanoma, Upper GI Tract Carcinoma
- Trial name
- NCT00753415
- Testing
- V935, V934-EP
- Volunteers
- 37 people
- Sponsor
- Merck Sharp & Dohme LLC
Barrett Esophagus, Esophageal Dysplasia
trūFreeze® Spray Cryotherapy Patient Registry
To collect efficacy and outcomes data related to the use of trūFreeze® spray cryotherapy for the treatment of unwanted tissue in the pulmonary and gastrointestinal settings.
- Conditions
- Barrett Esophagus, Esophageal Dysplasia, Esophageal Neoplasm, Esophageal Stenosis
- Trial name
- NCT01802203
- Testing
- truFreeze Spray Cryotherapy
- Where
- 16 sites in United States
- Volunteers
- 275 people
- Sponsor
- US Endoscopy Group Inc.
Leakage After Esophagectomy, Leakage After Gastrectomy
Eso-Sponge Registry
This international, prospective and multicenter registry was designed to collect clinical evidence for the endoscopic vacuum treatment using Eso-SPONGE® for anastomotic leakage after esophageal resection or iatrogenic or…
- Conditions
- Leakage After Esophagectomy, Leakage After Gastrectomy, Perforation of the Esophagus
- Trial name
- NCT02662777
- Testing
- Eso-SPONGE® vacuum treatment
- Where
- 17 sites in Germany
- Volunteers
- 108 people
- Sponsor
- Aesculap AG
Gastrointestinal Disease, Signs and Symptoms, Digestive
Nexium Dyspepsia/AST
The aim is to evaluate if the resolution of upper abdominal symptoms (pain or burning) during an acid suppressive test trial of esomprazole given daily for 7 days predicts symptoms resolution at the end of a subsequent treatment…
- Conditions
- Gastrointestinal Disease, Signs and Symptoms, Digestive, Dyspepsia
- Trial name
- NCT00251992
- Testing
- Esomeprazole
- Where
- 183 sites in Austria, Belgium and 11 more
- Volunteers
- 1,200 people
- Sponsor
- AstraZeneca
Gallbladder Disease, Biliary Colic
Fluorescence Imaging on the da Vinci Surgical System for Intra-operative Near Infrared Imaging of the Biliary Tree (up to 2-weeks Post-operatively)
The investigators hypothesize that the da Vinci Fluorescence Imaging Vision System provides real-time endoscopic near infrared fluorescence imaging of the biliary anatomy as defined as identifying biliary vessels; either cystic…
- Conditions
- Gallbladder Disease, Biliary Colic, Gallstones
- Trial name
- NCT01410734
- Testing
- Indocyanine green (ICG)
- Where
- 2 sites in Italy, Switzerland
- Volunteers
- 72 people
- Sponsor
- Intuitive Surgical
Gastrointestinal Disease, Signs and Symptoms, Digestive
Nexium Dyspepsia/AST
The aim is to evaluate if the resolution of upper abdominal symptoms (pain or burning) during an acid suppressive test trial of esomprazole given daily for 7 days predicts symptoms resolution at the end of a subsequent treatment…
- Conditions
- Gastrointestinal Disease, Signs and Symptoms, Digestive, Dyspepsia
- Trial name
- NCT00251914
- Testing
- Esomeprazole
- Where
- 215 sites in Argentina, Belgium and 15 more
- Volunteers
- 1,500 people
- Sponsor
- AstraZeneca
Peptic Ulcer
AGN 201904 Versus Esomeprazole in the Prevention of Aspirin-induced Stomach or Upper Intestinal Damage in Healthy Volunteers
AGN 201904, a proton pump inhibitor, versus esomeprazole in the prevention of stomach or upper intestinal damage following administration of high-dose aspirin in healthy volunteers
- Trial name
- NCT00325715
- Testing
- AGN 201904, esomeprazole
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Allergan